From: Using Mendelian randomization study to assess the renal effects of antihypertensive drugs
Class | #SNPs | Beta | 95% CI | p |
---|---|---|---|---|
ACE inhibitors | 1 | 0.07 | −0.37, 0.51 | 0.76 |
ARBs | 1 | −0.06 | −0.70, 0.58 | 0.86 |
CCBs | 9 | −0.15 | −0.28, − 0.02 | 0.03 |
Alpha-adrenoceptor blockers | 6 | −0.10 | −0.25, 0.05 | 0.17 |
Adrenergic neuron blockers | 3 | −0.12 | −0.41, 0.16 | 0.39 |
Beta-adrenoceptor blockers | 7 | −0.04 | −0.17, 0.10 | 0.58 |
Centrally acting antihypertensives | 4 | −0.24 | −0.49, 0.01 | 0.06 |
Loop diuretics | 2 | 0.17 | −0.17, 0.52 | 0.33 |
PSDs and aldosterone antagonists | 4 | −0.14 | −0.56, 0.29 | 0.53 |
Renin inhibitors | 1 | −0.27 | −0.80, 0.27 | 0.33 |
Thiazides and related diuretics | 4 | −0.10 | −0.52, 0.32 | 0.63 |
Vasodilator antihypertensives | 8 | −0.07 | −0.23, 0.09 | 0.39 |